Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) announced the presentation of two posters which detailed novel preclinical research into complement biology and the inhibition of factor D by ACH-4471 during the XXVIth International Complement Workshop, September 4 – 8, 2016, in Kanazawa, Ishikawa, Japan.

Researchers from Achillion presented a poster entitled “Assessment of complement-mediated bacterial killing and the effect of a small molecule factor D inhibitor in vitro” that described the effect of inhibiting different complement pathways on bacterial killing via two critical mechanisms: lysis and opsonophagocytosis. A second poster from Achillion, entitled “Comparison of complement functional assays: Differential sensitivities of hemolysis and Wieslab assays to levels of complement proteins C5, factor B, and factor D,” detailed the similarities and differences between inhibition of the alternative versus classical pathway in in vitro assays of complement activity.

“As we build upon our broad knowledge of the complement system, we continue to learn more about the unique role of the alternative pathway, its distinctions from the classical and lectin pathways, and its potential advantages in the treatment of rare diseases,” commented Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion. “With this important and exciting research, we continue to highlight the potential of factor D inhibition and look forward to advancing our first orally-administered small molecule, ACH-4471, into phase 2 clinical trials for both C3G and PNH during the fourth quarter of this year.” (Original Source)

Shares of Achillion closed last Friday at $8.12, down $0.11 or -1.34%. ACHN has a 1-year high of $10.95 and a 1-year low of $5.57. The stock’s 50-day moving average is $8.64 and its 200-day moving average is $8.33.

On the ratings front, ACHN has been the subject of a number of recent research reports. In a report issued on August 24, Jefferies Co. analyst Eun Yang reiterated a Hold rating on ACHN. Separately, on August 8, Chardan’s Madhu Kumar reiterated a Sell rating on the stock and has a price target of $4.

According to, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Eun Yang and Madhu Kumar have a total average return of 0.5% and -6.6% respectively. Yang has a success rate of 54% and is ranked #1981 out of 4147 analysts, while Kumar has a success rate of 55% and is ranked #3507.

Overall, one research analyst has rated the stock with a Sell rating, 2 research analysts have assigned a Hold rating and one research analyst has given a a Buy rating to the stock. When considering if perhaps the stock is under or overvalued, the average price target is $9.00 which is 10.8% above where the stock closed last Friday.

Achillion Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, develops and commercializes innovative treatments for infectious diseases. The company is currently engaged in the development of antivirals for the treatment of chronic hepatitis C infection and resistant bacterial infections. Its products include ACH-3102, ACH-2684, Sovaprevir and ACH-3422.